Evaxion A/S (EVAX) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights positive financial performance with a cash runway extended to 2027 and revenue from MSD. Significant progress in R&D, particularly in oncology and infectious diseases, enhances the company's growth prospects. While there are potential risks in partnerships and production, the overall sentiment is positive, supported by optimistic guidance and ongoing partnership discussions. The Q&A section reveals strong interest in the company's pipeline and technology, further boosting confidence. Despite some uncertainties, the overall outlook is positive, suggesting a potential stock price increase of 2% to 8%.
Key Financial Performance
Cash Runway Extended to the second half of 2027, supported by a $7.5 million option exercise fee received from MSD and additional capital market funding sources.
Revenue Driven by MSD's $7.5 million option exercise fee, marking the first operational gain for the quarter.
Operating Expenses Slightly below last year and consistent with the previous quarter, with an expected operating cash flow of around $14 million for the year.
Net Financials $1.3 million for the quarter, driven by the debt conversion with the European Investment Bank (EIB) at an 89% share price premium.
Quarterly Income $4.6 million, primarily driven by revenue from MSD and financial income from the EIB debt conversion.
Equity Improved to $16.6 million, including a derivative liability with a net impact of $1.5 million.
Cash Balance $10.6 million at the end of the quarter, with additional cash inflows from MSD revenue and investor warrant exercises.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
EVX-B3 in-licensing by MSD: Historical in-licensing of EVX-B3 by MSD, providing significant cash and validation. MSD exercised their option on EVX-B3, marking the first-ever in-licensing of an AI-discovered vaccine candidate by a major pharma company. This deal brought a $7.5 million exercise fee and validates the AI-Immunology platform.
EVX-04 addition to pipeline: EVX-04, a novel therapeutic cancer vaccine for acute myeloid leukemia, has been added to the pipeline. It targets nonconventional antigens and is based on the AI-Immunology platform. Preclinical studies have been conducted, and next steps include GMP manufacturing and IND-enabling studies.
EVX-01 Phase II trial results: Presented two-year clinical outcome data at the ESMO Congress. Results showed a 75% objective overall response, sustained responses in 11 out of 12 patients, and a 34% conversion rate. Strong immunological activity was observed, with 81% of vaccine neoantigens being immunogenic.
Partnership discussions: Several ongoing partnership discussions are in progress, though market uncertainty affects the deal climate.
AI-Immunology platform enhancement: Expanded AI-Immunology platform with an automated vaccine design module, improving quality and reducing vaccine design time. The module has been applied to key R&D projects, optimizing vaccine candidates and accelerating development timelines.
Financial position: Cash runway extended to the second half of 2027, supported by a $7.5 million option exercise fee from MSD and additional capital market funding. Achieved $31.8 million in activities year-to-date, strengthening equity and financial stability.
Leadership transition: Dr. Helen Tayton-Martin appointed as the new CEO effective November 24, bringing extensive biotech leadership and partnership experience. This transition aligns with the next stages of Evaxion's strategy.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Uncertainty: Ongoing market uncertainty is affecting the deal climate, which could hinder the company's ability to secure partnerships and collaborations.
Relapse Challenges in Acute Myeloid Leukemia: Relapses remain a major challenge in treating acute myeloid leukemia, which could impact the success of the EVX-04 cancer vaccine.
Regulatory and Manufacturing Risks: The next steps for EVX-04 include GMP manufacturing and IND-enabling studies, which are subject to regulatory approvals and potential delays.
Financial Dependency on Partnerships: The company's financial strategy heavily relies on partnerships, such as the MSD deal, which introduces risks if future partnerships or milestone payments do not materialize.
Pipeline Adjustments: The removal of the EVX-02 program indicates a potential risk of resource allocation and focus on programs that may not yield results.
Supply Chain and Production Risks: The development of vaccines, including the use of the new automated vaccine design module, depends on seamless transitions from design to production, which could face disruptions.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
EVX-04 Development: EVX-04, a novel AI-designed cancer vaccine targeting acute myeloid leukemia, is progressing with GMP manufacturing and IND-enabling studies planned to prepare for a first-in-human study.
EVX-01 Progress: EVX-01, a personalized cancer vaccine, has shown promising two-year clinical outcome data with a 75% objective overall response and sustained immune responses, reinforcing its potential as a personalized immunotherapy.
AI-Immunology Platform Enhancements: The platform now includes an automated vaccine design module, reducing design time and costs, and accelerating development timelines for new and existing vaccines.
Cash Runway: The company has extended its cash runway to the second half of 2027, supported by a $7.5 million option exercise fee from MSD and other capital market activities.
Future Revenue Potential: The MSD deal for EVX-B3 includes potential future revenue of up to $592 million, validating the company's partnership strategy.
Business Development: Multiple partnership discussions are ongoing, with business development remaining a key priority for the company.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the key questions potential partners have about EVX-01, and what is the company's strategy for its development?
A:Potential partners are no longer questioning the quality of data or the platform's functionality. Instead, they are asking how the technology can be applied to other cancer indications and discussing manufacturing solutions. The company plans to out-license EVX-01 at its current development stage, allowing partners to decide on the next steps. A potential next step could be a larger randomized control arm study comparing EVX-01 plus standard care to standard care alone. The technology may also be applied to other high-mutational-burden cancers.
Q:What is the differentiation of EVX-04 in the AML program, and how does it work?
A:EVX-04 uses the AI-Immunology platform to analyze genomic and transcriptomic data, focusing on transcriptomic data to identify antigens expressed as RNA in tumors. It targets endogenous retroviral sequences from the dark genome, which are highly expressed in AML. This allows for an off-the-shelf vaccine approach that can be used across different tumor profiles and immune characteristics, supporting multiple patients with a single vaccine.
Q:What is the breadth of partnering conversations across the pipeline, and how have they evolved?
A:The company is engaged in multiple dialogues across its R&D pipeline, including oncology and infectious disease programs, as well as classical target discovery collaborations. Interest has increased following major data readouts, such as the EVX-01 Phase II data. The company aims to monetize both its in-house vaccine candidates and target discovery collaborations, but the timing of deals remains uncertain.
Q:What are the potential applications of the automated design module, and how can it be monetized?
A:The automated design module integrates multiple AI tools to streamline the process from target discovery to product candidate selection. It can be used for internal programs and potentially licensed to other companies to help them select and produce cost-effective antigens or targets. The module offers multiple monetization opportunities.
Q:What additional data will be presented at SITC for EVX-01, and how will it strengthen the narrative?
A:At SITC, the company will present data on EVX-01-induced T cell responses and deeper phenotypic analyses of patient samples collected before, during, and after therapy. Additional data from the extension phase of the EVX-01 trial, where six patients are receiving EVX-01 as monotherapy, will also be shared. This data will provide a deeper understanding of immune profiles and strengthen the case for EVX-01.
Q:What is the status of the MSD relationship and the evaluation of EVX-B2?
A:MSD is currently evaluating the data provided for EVX-B2 and conducting confirmatory analyses. The evaluation term has been extended, and a decision is expected in the first half of next year. The company is optimistic about out-licensing EVX-B2 to MSD.
Q:Review of Unclear Management Responses
A:Management avoided providing specific timelines or details on when partnering conversations would result in deals, citing the difficulty of speculating on timing. Additionally, they did not provide detailed data or outcomes for the ongoing confirmatory analyses by MSD for EVX-B2, only stating that the process is ongoing.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI Immunology
AI vaccine
Adaptimmune
Bank debt
Dr
ERVs
EVX cancer
EVX lead
European Investment
Helen
Immunology platform
Interim CEO
Investment Bank
MSD cash
RD development
Tayton Martin
USD equity
achievement
acute myeloid
cash flow
cash income
control
conversion debt
debt conversion
design module
end USD
evaluation period
example
exercise fee
experience
neoantigen
outcome
study
vaccine design
warrant
EVAX Transcript
Evaxion A/S (EVAX) Q1 2026 Earnings Call Transcript
Unknown5-7
The earnings call summary and Q&A reveal mixed signals. While the company has promising programs and a solid cash runway until 2027, the lack of concrete partnership updates and unproven scalability of the AI-Immunology platform pose risks. The financial performance is stable, but not exceptional, with a net loss in line with expectations. The operational changes and strategic focuses are promising but yet to show results. Given these factors, the stock is likely to remain stable over the next two weeks, resulting in a neutral rating.
Evaxion A/S (EVAX) Q4 2025 Earnings Call Transcript
Positive3-6
The earnings call summary and Q&A indicate a positive outlook for Evaxion. The financial performance shows improved revenue and reduced operational costs, leading to a better financial position. The extended cash runway and strengthened equity are positive indicators. Product development, particularly the progress of EVX-01 and potential of EVX-04, is promising. The AI-Immunology platform enhancements and ongoing partnerships add further optimism. Despite some uncertainties in responses, the overall sentiment is positive, suggesting a likely stock price increase in the short term.
Evaxion A/S (EVAX) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call highlights positive financial performance with a cash runway extended to 2027 and revenue from MSD. Significant progress in R&D, particularly in oncology and infectious diseases, enhances the company's growth prospects. While there are potential risks in partnerships and production, the overall sentiment is positive, supported by optimistic guidance and ongoing partnership discussions. The Q&A section reveals strong interest in the company's pipeline and technology, further boosting confidence. Despite some uncertainties, the overall outlook is positive, suggesting a potential stock price increase of 2% to 8%.
Evaxion A/S (EVAX) Q2 2025 Earnings Call Transcript
Unknown8-19
The earnings call presents a mixed outlook. Positive aspects include a solid cash position and business development pipeline, along with reduced losses. However, challenging financial markets, increased regulatory uncertainty, and dependency on partnerships pose significant risks. The Q&A session highlighted management's avoidance of specifics, adding uncertainty. Overall, the potential for partnerships and the Merck collaboration are positive, but the risks and uncertainties balance out, leading to a neutral sentiment.
EVAX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
